Veracyte, Inc. VCYT
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 581.78M | 561.90M | 541.74M | 517.15M | 495.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 581.78M | 561.90M | 541.74M | 517.15M | 495.14M |
| Cost of Revenue | 153.62M | 150.75M | 149.60M | 146.77M | 148.37M |
| Gross Profit | 428.16M | 411.15M | 392.15M | 370.37M | 346.77M |
| SG&A Expenses | 216.64M | 211.49M | 213.28M | 220.71M | 215.14M |
| Depreciation & Amortization | 13.46M | 13.11M | 13.23M | 13.15M | 13.43M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 493.27M | 468.72M | 456.30M | 451.45M | 446.20M |
| Operating Income | 88.51M | 93.19M | 85.44M | 65.70M | 48.94M |
| Income Before Tax | 118.25M | 116.02M | 90.75M | 68.20M | 31.01M |
| Income Tax Expenses | -8.60M | 1.54M | 2.73M | 1.85M | 693.00K |
| Earnings from Continuing Operations | 126.85 | 114.48 | 88.01 | 66.35 | 30.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 126.85M | 114.48M | 88.01M | 66.35M | 30.32M |
| EBIT | 88.51M | 93.19M | 85.44M | 65.70M | 48.94M |
| EBITDA | 110.05M | 114.02M | 106.93M | 87.12M | 71.31M |
| EPS Basic | 1.59 | 1.44 | 1.11 | 0.84 | 0.39 |
| Normalized Basic EPS | 0.84 | 0.87 | 0.83 | 0.66 | 0.49 |
| EPS Diluted | 1.54 | 1.40 | 1.08 | 0.82 | 0.38 |
| Normalized Diluted EPS | 0.82 | 0.85 | 0.82 | 0.65 | 0.49 |
| Average Basic Shares Outstanding | 319.19M | 317.41M | 315.83M | 314.32M | 312.75M |
| Average Diluted Shares Outstanding | 327.54M | 324.45M | 320.78M | 319.53M | 318.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |